Full Name
Luca Valenti
Job Title
Professor
Company/Institution/ Organization
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy / Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy
Speaker Bio
Prof. Luca Valenti is an expert in Internal Medicine with a specialization in hepatology and metabolic diseases. After a period of training at Columbia University in New York, he dedicated his career to the research and treatment of complex liver diseases, with a particular focus on hepatic steatosis, non-alcoholic steatohepatitis (NASH), metabolic disorders of iron, viral hepatitis, and genetic liver diseases.
He graduated in Medicine and Surgery in 2000 from the University of Milan and completed his specialization in Internal Medicine at the same institution. Since 2016, he has been an Associate Professor of Internal Medicine at the University of Milan, working in collaboration with the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, where he leads an integrated Internal Medicine and Hepatology service. He is also the Head of the Translational Medicine Research Unit and the Scientific Supervisor at the Complex Operational Unit of Transfusional Medicine and Hematology.
In addition to his teaching roles in Clinical Medicine and Pathologic Basis of Diseases, he is a member of numerous scientific committees, including the Scientific Committee and Governing Board of the European Association for the Study of Liver (EASL), and serves as the Coordinator of the Rare Diseases Commission of the Italian Association for the Study of the Liver (AISF). He is also an honorary member of the Institute of Hepatology, Liver Trust, at King's College London.
Prof. Valenti is recognized as one of the leading global experts in the field of hepatic steatosis, dysmetabolic hyperferritinemia, and the study of genetic factors predisposing to liver diseases. He is the author of the Italian Guidelines and the European Guidelines for the clinical management of hepatic steatosis and non-alcoholic steatohepatitis, and was ranked among the top 10 global experts in hepatic steatosis by Experscape (2021).
As Editor-in-Chief of Liver International, he has received numerous awards for his research and has coordinated international clinical trials for the development of new treatments for non-alcoholic steatohepatitis. He is also a member of the Regional Technical Committee for the clinical management of NASH and is part of an international consortium that redefined the nomenclature and definition of metabolic hepatic steatosis.
His work continues to significantly impact the fields of hepatic and metabolic medicine, making substantial contributions to scientific research and the development of new treatments for liver diseases.
He graduated in Medicine and Surgery in 2000 from the University of Milan and completed his specialization in Internal Medicine at the same institution. Since 2016, he has been an Associate Professor of Internal Medicine at the University of Milan, working in collaboration with the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, where he leads an integrated Internal Medicine and Hepatology service. He is also the Head of the Translational Medicine Research Unit and the Scientific Supervisor at the Complex Operational Unit of Transfusional Medicine and Hematology.
In addition to his teaching roles in Clinical Medicine and Pathologic Basis of Diseases, he is a member of numerous scientific committees, including the Scientific Committee and Governing Board of the European Association for the Study of Liver (EASL), and serves as the Coordinator of the Rare Diseases Commission of the Italian Association for the Study of the Liver (AISF). He is also an honorary member of the Institute of Hepatology, Liver Trust, at King's College London.
Prof. Valenti is recognized as one of the leading global experts in the field of hepatic steatosis, dysmetabolic hyperferritinemia, and the study of genetic factors predisposing to liver diseases. He is the author of the Italian Guidelines and the European Guidelines for the clinical management of hepatic steatosis and non-alcoholic steatohepatitis, and was ranked among the top 10 global experts in hepatic steatosis by Experscape (2021).
As Editor-in-Chief of Liver International, he has received numerous awards for his research and has coordinated international clinical trials for the development of new treatments for non-alcoholic steatohepatitis. He is also a member of the Regional Technical Committee for the clinical management of NASH and is part of an international consortium that redefined the nomenclature and definition of metabolic hepatic steatosis.
His work continues to significantly impact the fields of hepatic and metabolic medicine, making substantial contributions to scientific research and the development of new treatments for liver diseases.
Speaking At
